NPSP up +8.62% percent right now. $NPSP High is at 29.45 and the Low 26.00 with current volume of 1,483,602.
Recent News posted below.
NPSP NPS Pharmaceuticals Recent Headline News
NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 55 mins ago
NPS Pharma (NPSP) reported a loss of 2 cents per share in the third quarter of 2014, wider than the year-ago loss of 1 cent per share.
AUXL: 32.56 (-0.14), NPSP: 29.43 (+2.52), AMGN: 163.20 (+0.11), BIOD: 1.52 (+0.02)
Barbarian At The Gate: NPS Pharmaceuticals (NPSP)
at The Street - 1 hr 18 mins ago
Trade-Ideas LLC identified NPS Pharmaceuticals (NPSP) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
NPSP: 29.43 (+2.52)
NPS Pharma ups revenues 46% in Q3
Seeking Alpha - at Seeking Alpha - 1 hr 46 mins ago
NPSP: 29.43 (+2.52)
NPS Pharmaceuticals' (NPSP) CEO Francois Nader on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:22PM CST
NPSP: 29.43 (+2.52)
NPS reports 3Q loss
Automated Insights - Mon Nov 10, 3:39PM CST
BEDMINSTER, N.J. (AP) _ NPS Pharmaceuticals Inc. (NPSP) on Monday reported a loss of $2.1 million in its third quarter.
NPSP: 29.43 (+2.52)
NPS Pharmaceuticals (NPSP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 3:25PM CST
NPSP: 29.43 (+2.52)
NPS Pharmaceuticals misses by $0.04, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:08PM CST
NPSP: 29.43 (+2.52)
NPS Pharma Reports Third-Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 3:01PM CST
--Company on track to meet full-year financial guidance
NPSP: 29.43 (+2.52)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 16.47 (+0.08), LLY: 68.49 (+0.14), CNCE: 13.52 (+0.15), OPK: 8.54 (-0.09), AZN: 74.22 (+1.01), ALXN: 195.69 (-0.11), ICPT: 173.51 (-2.84), NPSP: 29.43 (+2.52), XLRN: 33.19 (+0.93)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST
HK: 2.91 (-0.34), WWD: 48.28 (-3.53), LLNW: 2.66 (+0.16), FXEN: 2.71 (-0.14), RMTI: 11.10 (+0.20), CZR: 11.02 (-0.52), EGY: 6.91 (-0.08), ICUI: 81.98 (+10.17), ICEL: 7.47 (-0.23), SAAS: 9.13 (+0.16), DMD: 5.84 (-1.29), NPSP: 29.43 (+2.52), SCLN: 8.20 (+0.10), ATHX: 1.51 (-0.03), CMLS: 3.18 (-0.11), TC: 2.15 (+0.19), ATW: 36.08 (-1.68), CLUB: 6.07 (-0.70), RAX: 42.53 (+5.21), PTLA: 27.41 (-0.24), IPAR: 28.91 (-0.31), ATLS: 37.00 (+0.13), AMBC: 24.40 (+1.03), CUI: 8.45 (+0.03), PDLI: 8.15 (+0.22), OMER: 18.65 (+1.16), PRAA: 61.65 (-2.20), CARA: 8.63 (-0.12), HALO: 8.92 (-0.40), MODN: 10.52 (+0.42), CALL: 8.70 (-1.79), ASEI: 47.73 (-8.36), HGR: 20.74 (+0.15), ERII: 4.50 (-0.48)
NPS Pharmaceuticals - Why We Don't Agree With Price Targets But Still See 15% Upside
L&F Capital Management - Seeking Alpha - Fri Nov 07, 7:53AM CST
Quick Rundown of Company NPS Pharmaceuticals Inc. (NASDAQ: NPSP ) is a biotech company focused on the creation of treatment drugs for patients with rare gastrointestinal and endocrine disorders that are seriously unmet. To date, their lead product...
NPSP: 29.43 (+2.52)
Insider Trading Alert - NPSP, GPI And JDSU Traded By Insiders
at The Street - Wed Nov 05, 10:45AM CST
Stocks with insider trader activity include NPSP, GPI and JDSU
GPI: 87.23 (+0.69), JDSU: 13.53 (-0.10), NPSP: 29.43 (+2.52)
NPS Pharma Appoints Pierre Legault to Board of Directors
Business Wire - Tue Nov 04, 3:30PM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced the appointment of Pierre Legault, MBA, CA, CPA to its board of directors. Mr. Legault is chief executive officer of NephroGenex, Inc. He previously served as CEO at Prosidion, Ltd. and has held senior positions at OSI Pharmaceuticals, Eckerd, Rite Aid Corporation, and Sanofi-Aventis.
NRX: 4.22 (-0.02), NPSP: 29.43 (+2.52)
First Week of December 20th Options Trading For NPS Pharmaceuticals (NPSP)
DividendChannel.com - Mon Nov 03, 9:54AM CST
Investors in NPS Pharmaceuticals Inc. saw new options become available this week, for the December 20th expiration.
NPSP: 29.43 (+2.52)
NPS Pharma reports November 10
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 9:00AM CST
NPSP: 29.43 (+2.52)
NPS Pharma to Report Third Quarter 2014 Financial Results
Business Wire - Mon Nov 03, 7:10AM CST
NPS Pharmaceuticals, Inc. (Nasdaq:NPSP) announced today that it will report its third quarter 2014 financial results on Monday, November 10, 2014 at approximately 4:00 p.m. ET. The press release will be followed by a conference call and webcast at 4:30 p.m. ET.
NPSP: 29.43 (+2.52)
Insider Trading Alert - NPSP, CB And SPLK Traded By Insiders
at The Street - Thu Oct 30, 10:15AM CDT
Stocks with insider trader activity include NPSP, CB and SPLK
NPSP: 29.43 (+2.52), CB: 101.81 (-0.06), SPLK: 66.57 (-0.19)
SmarTrend Watching for Potential Rebound in Shares of NPS Pharmaceuticals After 7.39% Loss
Comtex SmarTrend(R) - Fri Oct 24, 5:18PM CDT
NPS Pharmaceuticals (NASDAQ:NPSP) traded in a range yesterday that spanned from a low of $25.56 to a high of $28.49. Yesterday, the shares fell 7.4%, which took the trading range below the 3-day low of $27.41 on volume of 6.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NPSP: 29.42 (+2.51)
Ford and Amazon are big market movers
AP - Fri Oct 24, 3:52PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
MMM: 156.74 (-0.92), AMZN: 310.73 (+5.62), F: 14.17 (+0.17), CAB: 50.90 (+0.14), CTXS: 67.00 (+0.19), JNPR: 20.67 (-0.83), DRIV: 24.54 (-0.23), TSCO: 73.38 (-0.26), P: 18.67 (+0.17), NPSP: 29.41 (+2.50), DAN: 20.21 (-0.08), CAT: 102.06 (-0.15), PG: 89.57 (+0.12), INFN: 14.38 (+0.01)
3 Money-Making Biotech Stocks That Could Go Higher
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 24, 7:34AM CDT
Biotechnology investors often have to make bets based more on promise than profit. That's because it takes years and hundreds of millions of dollars to advance new medicine through clinical trials to market, so investing in biotech stocks is more of...
INSY: 39.89 (+2.83), ANIP: 48.17 (-0.04), AMGN: 163.20 (+0.11), NPSP: 29.38 (+2.47), TEVA: 58.49 (+0.45)
Recent News posted below.
NPSP NPS Pharmaceuticals Recent Headline News
NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 55 mins ago
NPS Pharma (NPSP) reported a loss of 2 cents per share in the third quarter of 2014, wider than the year-ago loss of 1 cent per share.
AUXL: 32.56 (-0.14), NPSP: 29.43 (+2.52), AMGN: 163.20 (+0.11), BIOD: 1.52 (+0.02)
Barbarian At The Gate: NPS Pharmaceuticals (NPSP)
at The Street - 1 hr 18 mins ago
Trade-Ideas LLC identified NPS Pharmaceuticals (NPSP) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
NPSP: 29.43 (+2.52)
NPS Pharma ups revenues 46% in Q3
Seeking Alpha - at Seeking Alpha - 1 hr 46 mins ago
NPSP: 29.43 (+2.52)
NPS Pharmaceuticals' (NPSP) CEO Francois Nader on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:22PM CST
NPSP: 29.43 (+2.52)
NPS reports 3Q loss
Automated Insights - Mon Nov 10, 3:39PM CST
BEDMINSTER, N.J. (AP) _ NPS Pharmaceuticals Inc. (NPSP) on Monday reported a loss of $2.1 million in its third quarter.
NPSP: 29.43 (+2.52)
NPS Pharmaceuticals (NPSP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 3:25PM CST
NPSP: 29.43 (+2.52)
NPS Pharmaceuticals misses by $0.04, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:08PM CST
NPSP: 29.43 (+2.52)
NPS Pharma Reports Third-Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 3:01PM CST
--Company on track to meet full-year financial guidance
NPSP: 29.43 (+2.52)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 16.47 (+0.08), LLY: 68.49 (+0.14), CNCE: 13.52 (+0.15), OPK: 8.54 (-0.09), AZN: 74.22 (+1.01), ALXN: 195.69 (-0.11), ICPT: 173.51 (-2.84), NPSP: 29.43 (+2.52), XLRN: 33.19 (+0.93)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST
HK: 2.91 (-0.34), WWD: 48.28 (-3.53), LLNW: 2.66 (+0.16), FXEN: 2.71 (-0.14), RMTI: 11.10 (+0.20), CZR: 11.02 (-0.52), EGY: 6.91 (-0.08), ICUI: 81.98 (+10.17), ICEL: 7.47 (-0.23), SAAS: 9.13 (+0.16), DMD: 5.84 (-1.29), NPSP: 29.43 (+2.52), SCLN: 8.20 (+0.10), ATHX: 1.51 (-0.03), CMLS: 3.18 (-0.11), TC: 2.15 (+0.19), ATW: 36.08 (-1.68), CLUB: 6.07 (-0.70), RAX: 42.53 (+5.21), PTLA: 27.41 (-0.24), IPAR: 28.91 (-0.31), ATLS: 37.00 (+0.13), AMBC: 24.40 (+1.03), CUI: 8.45 (+0.03), PDLI: 8.15 (+0.22), OMER: 18.65 (+1.16), PRAA: 61.65 (-2.20), CARA: 8.63 (-0.12), HALO: 8.92 (-0.40), MODN: 10.52 (+0.42), CALL: 8.70 (-1.79), ASEI: 47.73 (-8.36), HGR: 20.74 (+0.15), ERII: 4.50 (-0.48)
NPS Pharmaceuticals - Why We Don't Agree With Price Targets But Still See 15% Upside
L&F Capital Management - Seeking Alpha - Fri Nov 07, 7:53AM CST
Quick Rundown of Company NPS Pharmaceuticals Inc. (NASDAQ: NPSP ) is a biotech company focused on the creation of treatment drugs for patients with rare gastrointestinal and endocrine disorders that are seriously unmet. To date, their lead product...
NPSP: 29.43 (+2.52)
Insider Trading Alert - NPSP, GPI And JDSU Traded By Insiders
at The Street - Wed Nov 05, 10:45AM CST
Stocks with insider trader activity include NPSP, GPI and JDSU
GPI: 87.23 (+0.69), JDSU: 13.53 (-0.10), NPSP: 29.43 (+2.52)
NPS Pharma Appoints Pierre Legault to Board of Directors
Business Wire - Tue Nov 04, 3:30PM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced the appointment of Pierre Legault, MBA, CA, CPA to its board of directors. Mr. Legault is chief executive officer of NephroGenex, Inc. He previously served as CEO at Prosidion, Ltd. and has held senior positions at OSI Pharmaceuticals, Eckerd, Rite Aid Corporation, and Sanofi-Aventis.
NRX: 4.22 (-0.02), NPSP: 29.43 (+2.52)
First Week of December 20th Options Trading For NPS Pharmaceuticals (NPSP)
DividendChannel.com - Mon Nov 03, 9:54AM CST
Investors in NPS Pharmaceuticals Inc. saw new options become available this week, for the December 20th expiration.
NPSP: 29.43 (+2.52)
NPS Pharma reports November 10
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 9:00AM CST
NPSP: 29.43 (+2.52)
NPS Pharma to Report Third Quarter 2014 Financial Results
Business Wire - Mon Nov 03, 7:10AM CST
NPS Pharmaceuticals, Inc. (Nasdaq:NPSP) announced today that it will report its third quarter 2014 financial results on Monday, November 10, 2014 at approximately 4:00 p.m. ET. The press release will be followed by a conference call and webcast at 4:30 p.m. ET.
NPSP: 29.43 (+2.52)
Insider Trading Alert - NPSP, CB And SPLK Traded By Insiders
at The Street - Thu Oct 30, 10:15AM CDT
Stocks with insider trader activity include NPSP, CB and SPLK
NPSP: 29.43 (+2.52), CB: 101.81 (-0.06), SPLK: 66.57 (-0.19)
SmarTrend Watching for Potential Rebound in Shares of NPS Pharmaceuticals After 7.39% Loss
Comtex SmarTrend(R) - Fri Oct 24, 5:18PM CDT
NPS Pharmaceuticals (NASDAQ:NPSP) traded in a range yesterday that spanned from a low of $25.56 to a high of $28.49. Yesterday, the shares fell 7.4%, which took the trading range below the 3-day low of $27.41 on volume of 6.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NPSP: 29.42 (+2.51)
Ford and Amazon are big market movers
AP - Fri Oct 24, 3:52PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
MMM: 156.74 (-0.92), AMZN: 310.73 (+5.62), F: 14.17 (+0.17), CAB: 50.90 (+0.14), CTXS: 67.00 (+0.19), JNPR: 20.67 (-0.83), DRIV: 24.54 (-0.23), TSCO: 73.38 (-0.26), P: 18.67 (+0.17), NPSP: 29.41 (+2.50), DAN: 20.21 (-0.08), CAT: 102.06 (-0.15), PG: 89.57 (+0.12), INFN: 14.38 (+0.01)
3 Money-Making Biotech Stocks That Could Go Higher
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 24, 7:34AM CDT
Biotechnology investors often have to make bets based more on promise than profit. That's because it takes years and hundreds of millions of dollars to advance new medicine through clinical trials to market, so investing in biotech stocks is more of...
INSY: 39.89 (+2.83), ANIP: 48.17 (-0.04), AMGN: 163.20 (+0.11), NPSP: 29.38 (+2.47), TEVA: 58.49 (+0.45)
